The APPG on Malaria & NTDs gathered on Tuesday, March 19th in Westminster at the Houses of Parliament. Jeremy Lefroy MP welcomed Rob van der Pluijm on behalf of the Mahidol-Oxford Tropical Medicine Research Unit (MORU), the Tracking Resistance to Artemesinin Collaboration II and the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project.
Rob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple ACTs, and the preliminary launch plans for the DeTACT Project in Africa and Asia. TRACII trials recruited over 1,000 patients across Asia with uncomplicated falciparum malaria. Results suggest TACTs are safe and highly efficacious even against multi-drug resistant falciparum malaria, currently highly prevalent in parts of SE Asia.
Read more (Worldwide Antimalarial Resistance Network website)